[go: up one dir, main page]

BR9812062A - Compound, use of this, process for preparing it, purified single enantiomer, pharmaceutical composition, and, processes for the treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal individual, and for treatment of asthma in a human or animal individual - Google Patents

Compound, use of this, process for preparing it, purified single enantiomer, pharmaceutical composition, and, processes for the treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal individual, and for treatment of asthma in a human or animal individual

Info

Publication number
BR9812062A
BR9812062A BR9812062-0A BR9812062A BR9812062A BR 9812062 A BR9812062 A BR 9812062A BR 9812062 A BR9812062 A BR 9812062A BR 9812062 A BR9812062 A BR 9812062A
Authority
BR
Brazil
Prior art keywords
treatment
human
animal individual
processes
pharmaceutical composition
Prior art date
Application number
BR9812062-0A
Other languages
Portuguese (pt)
Inventor
Geoffrey Duke Edward Clarke
Michael Dennis Dowle Britanico
Harry Finch
Lee Andrew Harrison
Graham George Adam Inglis
Martin Redpath Johnson
Simon John Fawcett Macdonald
Pritom Shah
Robin Andrew Smith
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9719189.4A external-priority patent/GB9719189D0/en
Priority claimed from GBGB9719183.7A external-priority patent/GB9719183D0/en
Priority claimed from GBGB9719290.0A external-priority patent/GB9719290D0/en
Priority claimed from GBGB9803611.4A external-priority patent/GB9803611D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9812062A publication Critical patent/BR9812062A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSTO, USO DESTE, PROCESSO PARA PREPARá-LO, ENANCIÈMERO úNICO PURIFICADO, COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAMENTO DE BRONQUITE CRÈNICA OU DE DOENçA PULMONAR OBSTRUTIVA CRÈNICA EM UM INDIVìDUO HUMANO OU ANIMAL, E PARA TRATAMENTO DE ASMA EM UM INDIVìDUO HUMANO OU ANIMAL" De acordo com a invenção, proporciona-se compostos de fórmula (I) em que R1, R2 e R3 são como definidos na descrição. Os compostos de fórmula (I) são úteis, inter alia, no tratamento de distúrbios inflamatórios do trato respiratório."COMPOSITE, USE OF THIS, PROCESS TO PREPARE IT, PURIFIED SINGLE ENANCIÈMERO, PHARMACEUTICAL COMPOSITION, AND, PROCESSES FOR THE TREATMENT OF CHRONIC BRONCHITIS OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN A HUMAN OR ANIMAL HUMAN INDIVIDUAL, ANIMAL "According to the invention, there are provided compounds of formula (I) in which R1, R2 and R3 are as defined in the description. The compounds of formula (I) are useful, inter alia, in the treatment of inflammatory disorders of the respiratory tract.

BR9812062-0A 1997-09-09 1998-09-07 Compound, use of this, process for preparing it, purified single enantiomer, pharmaceutical composition, and, processes for the treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal individual, and for treatment of asthma in a human or animal individual BR9812062A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9719189.4A GB9719189D0 (en) 1997-09-09 1997-09-09 New therapeutic method
GBGB9719183.7A GB9719183D0 (en) 1997-09-09 1997-09-09 Compounds
GBGB9719290.0A GB9719290D0 (en) 1997-09-10 1997-09-10 Compounds
GBGB9803611.4A GB9803611D0 (en) 1998-02-21 1998-02-21 Compounds
PCT/EP1998/005609 WO1999012933A2 (en) 1997-09-09 1998-09-07 Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase

Publications (1)

Publication Number Publication Date
BR9812062A true BR9812062A (en) 2000-09-26

Family

ID=27451698

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812062-0A BR9812062A (en) 1997-09-09 1998-09-07 Compound, use of this, process for preparing it, purified single enantiomer, pharmaceutical composition, and, processes for the treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal individual, and for treatment of asthma in a human or animal individual

Country Status (24)

Country Link
EP (1) EP1003748A2 (en)
JP (1) JP2001515904A (en)
KR (1) KR20010023766A (en)
CN (1) CN1278820A (en)
AP (1) AP2000001761A0 (en)
AR (1) AR017072A1 (en)
AU (1) AU9741298A (en)
BR (1) BR9812062A (en)
CA (1) CA2303176A1 (en)
CO (1) CO4970719A1 (en)
EA (1) EA200000204A1 (en)
EE (1) EE200000138A (en)
HU (1) HUP0004644A3 (en)
ID (1) ID24452A (en)
IL (1) IL134791A0 (en)
IS (1) IS5391A (en)
MA (1) MA26543A1 (en)
NO (1) NO20001198L (en)
NZ (1) NZ503130A (en)
PE (1) PE107899A1 (en)
PL (1) PL339176A1 (en)
SK (1) SK3192000A3 (en)
TR (1) TR200000907T2 (en)
WO (1) WO1999012933A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9905418D0 (en) * 1999-03-09 1999-05-05 Glaxo Group Ltd Process
AU2005231375A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3 receptor modulators
DE102004024772A1 (en) * 2004-05-17 2005-12-22 Grünenthal GmbH Substituted 5-aminomethyl-1H-pyrrole-2-carboxamides
JP4853759B2 (en) * 2004-05-27 2012-01-11 日本農薬株式会社 Substituted pyrazinecarboxylic acid anilide derivatives or salts thereof, intermediates thereof, agricultural and horticultural agents, and methods of use thereof
TWI355380B (en) * 2004-05-27 2012-01-01 Nihon Nohyaku Co Ltd Substituted pyrazinecarboxanilide derivatives or s
GB2418427A (en) 2004-09-02 2006-03-29 Univ Cambridge Tech Ligands for G-protein coupled receptors
ES2328384T3 (en) 2004-11-23 2009-11-12 Warner-Lambert Company Llc ACID DERIVATIVES 7- (2H-PIRAZOL-3-IL) -3,5-DIHIDROXI-HEPTANOICO AS INHIBITORS OF HMG CO-A REDUCTASE FOR THE TREATMENT OF LIPIDEMIA.
DE602007009095D1 (en) 2006-05-04 2010-10-21 Pulmagen Therapeutics Inflamma TETRAHYDROPYRROLOPYRIMIDINDIONE AND ITS USE AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
WO2009060206A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
EP4031138A1 (en) 2019-09-17 2022-07-27 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
AU2021256835A1 (en) 2020-04-16 2022-10-13 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211783D0 (en) * 1992-06-04 1992-07-15 Ici Plc Amide derivatives
GB9402680D0 (en) * 1994-02-11 1994-04-06 Zeneca Ltd Pyrrolidine derivatives
AR006401A1 (en) * 1996-03-28 1999-08-25 Glaxo Group Ltd PIRROLOPYROLONE COMPOUNDS, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT AND IN THERAPY, PROCESSES FOR ITS PREPARATION AND INTERMEDIARY COMPOUNDS FOR SUCH PROCESSES.

Also Published As

Publication number Publication date
IL134791A0 (en) 2001-04-30
PL339176A1 (en) 2000-12-04
CN1278820A (en) 2001-01-03
NZ503130A (en) 2001-08-31
SK3192000A3 (en) 2001-03-12
WO1999012933A3 (en) 1999-05-27
CO4970719A1 (en) 2000-11-07
PE107899A1 (en) 1999-11-17
AR017072A1 (en) 2001-08-22
NO20001198D0 (en) 2000-03-08
KR20010023766A (en) 2001-03-26
TR200000907T2 (en) 2000-11-21
EE200000138A (en) 2001-02-15
AU9741298A (en) 1999-03-29
EA200000204A1 (en) 2000-10-30
IS5391A (en) 2000-02-29
NO20001198L (en) 2000-05-08
CA2303176A1 (en) 1999-03-18
WO1999012933A2 (en) 1999-03-18
HUP0004644A3 (en) 2002-01-28
AP2000001761A0 (en) 2000-03-31
ID24452A (en) 2000-07-20
MA26543A1 (en) 2004-12-20
EP1003748A2 (en) 2000-05-31
JP2001515904A (en) 2001-09-25
HUP0004644A2 (en) 2001-09-28

Similar Documents

Publication Publication Date Title
BR9812062A (en) Compound, use of this, process for preparing it, purified single enantiomer, pharmaceutical composition, and, processes for the treatment of chronic bronchitis or chronic obstructive pulmonary disease in a human or animal individual, and for treatment of asthma in a human or animal individual
BR9907270A (en) Compound, pharmaceutical composition, use of a compound, and, processes for the treatment or prophylaxis of inflammatory diseases, for example, asthma or copd, and for the preparation of a compound
BR9907886A (en) Compound, use of it, pharmaceutical composition, and, treatment process or prophylaxis of inflammatory diseases, for example asthma or copd.
BR0310106A (en) Compound, process for producing a compound, pharmaceutical composition, use of the compound and method for treating a subject suffering from a pathological condition or disease
BR9911482A (en) Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
BR9911488A (en) Compound, use of it, pharmaceutical composition, and processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
BR9808953A (en) Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition
BR9916282A (en) Compound, use of a compound and method of treatment
BR9714082A (en) Compound, use thereof, pharmaceutical composition, and, processes for treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound.
CL2003002683A1 (en) ENANTIOMERS S OF COMPOUNDS DERIVED FROM ACID (2S) -3-4 (- {2-AMINO-2-OXOETOXI} PHENYL) -2-ETOXIPROPANOIC; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND ITS USE FOR THE TREATMENT OR PREVENTION OF LIPID DISORDERS,
BR9808812A (en) Composition comprising crystalline, finely divided budesonide particles
BRPI0413490A (en) new compounds
BR9812944A (en) Bicyclic kinase inhibitors
BRPI0407430A (en) Benzenesulfonic acid salt with clopidogrel, processes for its preparation, and for purification of clopidogrel, use of a salt, pharmaceutical formulation, active substance particles, use of active substance particles, and process for preparation of active substance particles
BRPI0409109A (en) new compounds
BR9815140A (en) "2-aryl-8-oxodidropurine derivatives, process for their production, medicinal compositions containing them, and their intermediates"
BR9810592A (en) Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound
PT1267866E (en) RESPIRATORY DISEASE TREATMENT
BR9813028A (en) Prostaglandin agonists and their use to treat bone disorders
BR9910832A (en) 2-adrenergic "beta" receptor agonists
BR0010716A (en) Phenyl compounds substituted with immunosuppressive activity and pharmaceutical compositions
BR0211450A (en) Therapeutic method
BR9811055A (en) Compound, use of it, pharmaceutical composition, and process for treating disease or medical condition mediated by factor xa
BRPI0409498A (en) use of a compound, pharmaceutical formulation, compound, pharmaceutical composition, and process for preparing a compound
BR0206935A (en) Compound, pharmaceutical formulation, use of a compound, method of treatment and / or prophylaxis of conditions associated with glycogen synthase kinase-3 inhibition, and process for preparing a compound

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]